Your browser doesn't support javascript.
loading
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
Pfeuffer, Steffen; Ruck, Tobias; Pul, Refik; Rolfes, Leoni; Korsukewitz, Catharina; Pawlitzki, Marc; Wildemann, Brigitte; Klotz, Luisa; Kleinschnitz, Christoph; Scalfari, Antonio; Wiendl, Heinz; Meuth, Sven G.
Afiliação
  • Pfeuffer S; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany steffen.pfeuffer@ukmuenster.de.
  • Ruck T; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Pul R; Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany.
  • Rolfes L; Department of Neurology, Universitat Duisburg-Essen, Duisburg, Germany.
  • Korsukewitz C; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Pawlitzki M; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Wildemann B; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Klotz L; Division of Molecular Neuroimmunology, Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
  • Kleinschnitz C; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Scalfari A; Department of Neurology, Universitat Duisburg-Essen, Duisburg, Germany.
  • Wiendl H; Centre for Neuroscience, Division of Experimental Medicine, Hammersmith Hospital, Imperial College London, London, UK.
  • Meuth SG; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
J Neurol Neurosurg Psychiatry ; 92(9): 1007-1013, 2021 09.
Article em En | MEDLINE | ID: mdl-33712515
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Alemtuzumab / Imunossupressores / Esclerose Múltipla Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: J Neurol Neurosurg Psychiatry Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Alemtuzumab / Imunossupressores / Esclerose Múltipla Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: J Neurol Neurosurg Psychiatry Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha